Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR) announced today that its drug candidate, rezpegaldesleukin, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ...